INTSEL CHIMOS
keyboard_backspaceBack to Home
Contact
1 rue Royale 162 Bureaux de la Colline
92213 SAINT CLOUD
France
CEO
About us
Intsel Chimos is a pharmaceutical company that has been operating as healthcare professionals’ partner since 1966. We specialize in the importation, provision, and the exploitation of innovative medicines and orphan drugs to treat patients in therapeutic stalemate who suffer from rare and/or serious diseases. Our extensive experience over the years has enabled us to build trusting and efficient relationships with hospitals, healthcare professionals, and many international partners.
Business offer
Intsel Chimos is your all in one pharmaceutical company with exploitant status in compliance with the French Public Health Code. We support our partners in accessing the market for products under compassionate use, early access as well as marketing authorization of registered products. We are offering comprehensive expertise across the entire product life cycle:
Intsel Chimos specializes in facilitating both early and market access providing comprehensive support to pharmaceutical companies introducing therapies into the French healthcare system — before and also after marketing authorization.
Additionally Intsel Chimos can assist your data collection and product distribution within the framework of clinical trials.
Benefits of working with Intsel Chimos
Intsel Chimos offers a comprehensive and integrated approach to help pharmaceutical companies navigate the complex regulatory and market landscape. Key benefits include:
- Integrated Services: From pharmacovigilance and quality assurance to strategic sales and marketing support, we ensure seamless products management and successful strategies.
- Customized Strategies: Regulatory, pricing, and reimbursement solutions designed to align with your specific product and market objectives.
- Continuity of Access: Full lifecycle management—from early access programs to post-Marketing Authorization support — ensuring consistent patient access to treatments.
- Compliance Excellence: Strict adherence to national and international standards (e.g., GVP, GMP, GDP, French Public Health Code) to ensure data integrity and sustained compliance.
- Operational Efficiency: Optimized timelines to accelerate market entry, in-house storage and distribution to secure the supply chain.
- Cross-therapeutic Expertise: Deep experience across multiple therapeutic areas including but not limited to rare diseases.
COMMITMENT
EFFICIENCY AND RELIABILITY
As a distinguished distributor and operator of
compassionate and/or early access medicines
(AAC/AAP), we provide solutions to patients whose
needs are unmet by treatments currently unavailable in the French
market.
COMPLIANCE AND LIABILITY
Intsel Chimos has acquired in-depth knowledge and
familiarity with the French and European healthcare
systems. We are fully dedicated to supporting our
parthers in navigating these systems successfully across
all therapeutic areas.
REACTIVITY AND FLEXIBILITY
Intsel Chimos has developed expertise that allows it to
be reactive and flexible in the acquisition and
distribution or various pharmaceutical specialties to
hospitals and community pharmacies.
As a pharmaceutical company, Intsel Chimos is committed to supporting it’s partners success at all stages : registration, marketing, and promotion of treatments. We aim to accomplish this in the simplest and most efficient way possible, while maintaining strict compliance with the French and European regulations.
Activities
- Therapeutic Product
- Service
- Consulting
- Cardiology
- Genetic Diseases
- Oncology
- Nervous Central System
- Hematology
- Infectiology
- Immunology
- Ophthalmology
- Inflammation
- Other
- Bioproduction
- Batch release
- Storage matter
- Instruction
- Logistic
- Clinical trials
- Phase I
- Phase II
- Phase III
- Phase IV
- Regulatory filing
- Regulatory Filing
- Post-market surveillance
- Post-Market Surveillance
- Bioproduction engineering
- Conditioning
- Storage
- Delivery
- Transport
- Supply chain logistics
- Tracking process
- Monitoring logistics
- Cell procurement
- Autologous
- Bioproduction/CMC/Analytical Quality Assessment, Quality Control
- Supply chain logistics
- Tracking process
- Monitoring logistics
- Clinical trials
- Phase I
- Phase II (human challenge trials)
- Phase III (large population pending pathogen prevalence)
- Immune monitoring
- Data management
- Vaccine shipment and distribution
- Storage matter
- Packaging for shipping
- Instruction Label
- Digitalization of bar code
- Cold chain logistics
- Regulatory Filing
- Regulatory Filing
- New Drug Application (IND)
- Investigational Medicinal Product (IMPT) for clinical investigations (EMA)
- Common Technical document (CTD) section 3 (CMC) 4 (NCS) and 5 (Clinics) for submission
- Post-market surveillance
- Clinical Trial phase IV
- Immune monitoring
